Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer
-
Form DEFA14A Chardan Healthcare Acqui
-
Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer
-
UPDATE: Chardan Capital Markets Starts Tenaya Therapeutics Inc (TNYA) at Buy
-
Abri SPAC I, Inc. Announces Closing of Over-Allotment Option in Connection With Its Initial Public Offering
-
Chardan NexTech Acquisition 2 Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing August 24, 2021
-
Form 8-K Chardan NexTech Acquisit For: Aug 23
-
Sonnet BioTherapeutics (SONN) Prices 35.3M Share+Warrant Offering at $0.85/sh
-
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
-
Form 8-K Chardan NexTech Acquisit For: Aug 13
-
Form DEFA14A Chardan Healthcare Acqui
-
Chardan NexTech Acquisition 2 Corp. Announces Closing of Underwriters' Over-Allotment Option to Purchase Additional Units in Connection with its Initial Public Offering
-
Form SC 13G Chardan NexTech Acquisit Filed by: MMCAP International Inc. SPC
-
Form 10-Q Chardan Healthcare Acqui For: Jun 30
-
Form NT 10-Q Chardan Healthcare Acqui For: Jun 30
-
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
-
Form 8-K Chardan NexTech Acquisit For: Aug 10
-
Chardan NexTech Acquisition 2 Corp. Announces Closing of Upsized $110 Million Initial Public Offering
-
Abri SPAC I, Inc. Announces Closing of $50 Million Initial Public Offering
-
Form 424B4 Chardan NexTech Acquisit
-
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
-
International Media Acquisition Corp. Announces the Separate Trading of its Common Stock, Rights and Warrants, Commencing August 17, 2021
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: Chardan NexTech Investments 2 LLC
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: PROPPER KERRY
-
Form S-1MEF Chardan NexTech Acquisit
-
Form EFFECT Chardan NexTech Acquisit
-
Chardan NexTech Acquisition 2 Corp. (CNTQU) Prices Upsized 11M Unit Offering at $10/unit
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: GROSSMAN JONAS
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: THOMSON TODD S
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: Weil Alex
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: Hardamon Roderick A.
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: Biele Jonathan C
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: Boyle Howarth Perry Jr.
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: Thakrar Hitesh
-
Form 3 Chardan NexTech Acquisit For: Aug 10 Filed by: Des Jardins Jory
-
Chardan NexTech Acquisition 2 Corp. Announces Pricing of Upsized $110 Million Initial Public Offering
-
Form CERT Chardan NexTech Acquisit
-
Form 8-A12B Chardan NexTech Acquisit
-
Chardan Co-Sponsors and Acts as Sole Bookrunner in CleanTech Acquisition Corp.'s $172.5 Million IPO
-
Abri SPAC I, Inc. (ASPAU) Prices 5M Unit IPO at $10/unit
-
Abri SPAC I, Inc. Announces Pricing of $50 Million Initial Public Offering on NASDAQ
-
ProQR Therapeutics N.V. (PRQR) PT Lowered to $18 at Chardan Capital Markets
-
International Media Acquisition Corp. Announces Exercise and Closing of Over-Allotment Option in Public Offering
-
Arrowhead Pharma (ARWR) PT Lowered to $94 at Chardan Capital Markets
-
Form S-1/A Chardan NexTech Acquisit
-
Form DEFM14A Chardan Healthcare Acqui
-
Form 425 Chardan Healthcare Acqui Filed by: Chardan Healthcare Acquisition 2 Corp.
-
Form 8-K Chardan Healthcare Acqui For: Jul 29
-
Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger
-
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

